Hormone Therapy 2016 Revised Global Consensus Statement

“The Revised Global Consensus Statement on
Menopausal Hormone Therapy is aimed at
updating and expanding the areas of consensus”.1

Umbrella
What may the Hormone Therapy 2016 Revised Global Consensus Statement Umbrella include?

Depending on the Source (DotS) this Umbrella may include:

  • Hormone Replacement Therapy (HRT)
  • Hormone Therapy (HT)
  • Menopausal Hormone Therapy (MHT)
  • Revised Global Consensus Statement on Menopausal Hormone Therapy

Revised Global Consensus Statement

What is the Revised Global Consensus Statement on Menopausal Hormone Therapy?

In the Revised Global Consensus Statement on Menopausal Hormone Therapy (Revised Global Consensus Statement) – endorsed by seven menopause-related organizations – published online 20 June 2016, the authors explain:

“The publication of the Global Consensus on Menopausal Hormone Therapy in 2013 by leading global menopause societies succeeded in presenting guidelines in a troubled therapeutic area that are helpful to both health-care providers and potential users of menopausal hormone therapy (MHT). The revised statement is aimed at updating and expanding the areas of consensus”.2

Organizations

Which organizations endorse the Revised Global Consensus Statement?

Organizations which endorse the Revised Global Consensus Statement (in alphabetical order) are the:

Organizations

  1. Asia Pacific Menopause Federation
  2. Endocrine Society
  3. European Menopause and Andropause Society
  4. Federation of Latin American Menopause Societies
  5. International Menopause Society
  6. International Osteoporosis Foundation
  7. North American Menopause Society

Informed Decision

What are the Revised Global Consensus Statement authors hopeful of?

The Revised Global Consensus Statement authors note:

“Hopefully, this statement will enable health-care providers to offer those women in midlife, who may benefit from MHT, the opportunity to make an informed decision”.3

Acknowledgement

What do the Revised Global Consensus Statement authors acknowledge?

The Revised Global Consensus Statement authors acknowledge:

“The revised statement contains only areas of consensus and does not replace the more detailed and fully referenced recommendations of the individual societies (referenced at the end of the document)”.4

Consensus

What are some points of consensus in the Revised Global Consensus Statement?

Some points of consensus are:

Hormone Therapy 2016 Revised Global Consensus Statement

  • “MHT, including tibolone and the combination of conjugated equine estrogens and bazedoxifene (CE/BZA), is the most effective treatment for vasomotor symptoms (VMS) associated with menopause at any age, but benefits are more likely to outweigh risks if initiated for symptomatic women before the age of 60 years or within 10 years after menopause
  • If MHT is contraindicated or not desired for treatment of VMS, selective serotonin reuptake inhibitors and serotoninnorepinephrine reuptake inhibitors such as paroxetine, escitalopram, venlafaxine and desvenlafaxine, which have been shown to be effective in randomized controlled trials (RCTs), may be considered. Gabapentin may also be considered
  • Local low-dose estrogen therapy is preferred for women whose symptoms are limited to vaginal dryness or associated discomfort with intercourse or for the prevention of recurrent urinary tract infections”.5

Vasomotor Symptoms

What are vasomotor symptoms?

DotS the definition of vasomotor symptoms may vary. The North American Menopause Society’s definition is:

“Vasomotor symptoms. Also known as hot flashes and night sweats, common symptoms during perimenopause and early postmenopause”.6

Health Care Provider

What if I choose to use MHT?

If you choose to use MHT, it may be in your best interest to also choose to talk to your health care provider about this.

One of the points of consensus in the Revised Global Consensus Statement is:

  • “The option of MHT is an individual decision in terms of quality of life and health priorities as well as personal risk factors such as age, time since menopause and the risk of VTE, stroke, ischemic heart disease and breast cancer. MHT should not be recommended without a clear indication for its use”.7

What is VTE?

MHT can be an abbreviation for Venous Thromboembolism.

Health Topics A-Z

Where may I find Health Topics related to Hormone Therapy 2016 Revised Global Consensus Statement?

In Health Topics A-Z you may find:

Health Topics A-Z

Links

Where may I find Links related to Hormone Therapy 2016 Revised Global Consensus Statement?

Your Country may have Links similar to:

Links

This Links List to third party websites is neither comprehensive nor exhaustive. Inclusion on this Links List does not imply endorsement or recommendation. Non-inclusion on this Links List does not imply non-endorsement or non-recommendation. Third party websites are not under the control of Meno Martha International Menopause Directory. Third party websites may contain explicit medical images and/or sexual references. Please read Meno Martha International Menopause Directory’s Links Policy before proceeding to a Link. Please contact Webmaster if you experience a problem with a Link.

  1. 2016 IMS Recommendations on Women’s Midlife Health and Menopause Hormone Therapy
  2. 9 Myths and Misunderstandings About Menopausal Hormone Therapy (MHT)
  3. Askearlymenopause.org [Ask EM] [+ Video: What Is Early Menopause?]
  4. BMS & WHC’s 2020 Recommendations on Hormone Replacement Therapy In Menopausal Women
  5. Bioidentical Custom Compounded Hormone Therapy
  6. Bioidentical Hormone Therapy
  7. Bioidentical Hormones Explained – A British Menopause Society Video
  8. Bioidentical Hormones: Are They Safer?
  9. Combined Menopausal Hormone Therapy (MHT)
  10. Complementary Medicine Options for Menopausal Symptoms
  11. Complementary and Alternative Therapies Explained – A British Menopause Society Video
  12. Compounded Bioidentical Hormone Therapy [Video]
  13. Compounded Bioidentical Hormones In Endocrinology Practice: An Endocrine Society Scientific Statement
  14. Deciding About Hormone Therapy
  15. EMAS Replay
  16. EMAS Replay: Risk Assessment for MHT – When, To Whom, Which, and How Long?
  17. EMAS Replay: The Relevance of Estrogen and Progestogen Choice for Breast Safety During MHT [Multiply Languages]
  18. Early Menopause: Experiences and Perspectives of Women and Health Practitioners – Women’s Profiles
  19. Estrogen & Hormones: Estrogen & Heart Disease
  20. Fast Facts: HRT and Breast Cancer Risk
  21. Find A Menopause Practitioner [United States and Other]
  22. Find An AMS Doctor [Australasian Menopause Society i.e. Australia and New Zealand]
  23. Find Your Nearest BMS Menopause Specialist [British Menopause Society]
  24. Global Consensus Statement on Menopausal Hormone Therapy
  25. HRT and Bleeding Explained – A British Menopause Society Video
  26. HRT and Breast Cancer: Overall Risks and Benefits Explained – A British Menopause Society Video
  27. HRT and the Risk of Breast Cancer Explained – A British Menopause Society Video
  28. HRT: Benefits and Risks
  29. HRT: The History
  30. HRT: Types, Doses and Regimens
  31. Hormone Help Desk: ET, EPT, and More
  32. Hormone Replacement Therapy
  33. Hormone Replacement Therapy (HRT)
  34. Hormone Replacement Therapy (HRT) Explained – A British Menopause Society Video
  35. Hormone Replacement Therapy (HRT): Risks of HRT
  36. Hormone Replacement Therapy (HRT): Types
  37. Hormone Therapy: Is It Right for You?
  38. Hormones After Age 65 Are OK for Some Women
  39. Hot Flashes: Manage Without Medication?
  40. Hot Flashes: What Can I Do?
  41. Jean Hailes MHT Position Statement
  42. Lifestyle and Behavioural Modifications for Menopausal Symptoms
  43. MHT Still Maligned & Misunderstood: Expert
  44. MHT and Breast Cancer Risk
  45. Making Choices At Menopause
  46. Making Sense of Menopausal Hormone Therapy Means Understanding the Benefits As Well As the Risks
  47. Mayo Clinic Q and A: Estrogen Replacement Therapy After Ovary Removal
  48. Menopausal Hormone Therapy
  49. Menopausal Hormone Therapy Trends Before Versus After 2002: Impact of the Women’s Health Initiative Study Results
  50. Menopausal Hormone Therapy and Breast Cancer Risk
  51. Menopausal Hormone Therapy and Venous Thromboembolism
  52. Menopausal Hormone Therapy and Women’s Health: An Umbrella Review
  53. Menopausal Hormone Therapy, Heart Disease and Stroke
  54. Menopause
  55. Menopause
  56. Menopause
  57. Menopause & Hormones: Questions To Ask Your Doctor
  58. Menopause FAQs: Hormone Therapy for Menopause Symptoms
  59. Menopause Hormone Therapy and Your Heart
  60. Menopause Hormone Therapy: Follow-Up Appointments
  61. Menopause Hormone Therapy: Who Shouldn’t Take It?
  62. Menopause Map: Downloadable Resources – My Personal Path Print Tools: Menopause Medication Tracker
  63. Menopause Map: Downloadable Resources – My Personal Path Print Tools: Questions for Your Health Care Provider
    Hormone Therapy 2016 Revised Global Consensus Statement
  64. Menopause Symptoms and Relief
  65. Menopause Treatment
  66. Menopause Treatment
  67. Menopause: Diagnosis and Management – Information for the Public: Questions To Ask About Menopause [NICE Guideline]
  68. Menopause: Is Menopausal Hormone Therapy (HRT) Safe? [Multiply Languages] [Video]
  69. Menopause: Medicines To Help You
  70. Menopause: Menopause – Hormone Treatments
  71. Menopause: Non-Hormonal Treatment & Relief for Hot Flashes
  72. Menopause: What Is Menopausal Hormone Therapy (HRT)? [Multiply Languages] [Video]
  73. NAMS 2017 Position Statement Updates Guidelines for Hormone Therapy Use
  74. NAMS Supports Judicious Use of Systemic Hormone Therapy for Women Aged 65 Years and Older
  75. National Center for Complementary and Integrative Health: Know the Science: How Medications and Supplements Can Interact
  76. National Center for Complementary and Integrative Health: Menopausal Symptoms In Depth
  77. Non Estrogen-Treatments for Menopausal Symptoms
  78. Oestrogen Only Menopausal Hormone Therapy
  79. Revised Global Consensus Statement on Menopausal Hormone Therapy
  80. Risks and Benefits of MHT
  81. The Menopause: Hormone Replacement Therapy (HRT) [+ Video: Is HRT Bad for You?]
  82. The North American Menopause Society Statement on Continuing Use of Systemic Hormone Therapy After Age 65
  83. Types of Hormone Therapy
  84. Understanding Menopause – Booklet
  85. Understanding Premature & Early Menopause – Booklet
  86. Urogenital Atrophy Explained – A British Menopause Society Video
  87. Using HRT (Hormone Replacement Therapy)
  88. Vaginal Dryness
  89. Vaginal Dryness
  90. Video Gallery [Menopause, The Journal of the North American Menopause Society]
  91. Video Series-2021: Treatment Options for Vaginal Dryness and Urinary Issues
  92. Video Series-2021: What Women Need to Know About Hormone Therapies
  93. Video Series-2022: Hormone Therapy: Understanding the Risks and Benefits
  94. Video Series-2022: New Treatment Options for Menopause Symptoms Are Around the Corner
  95. Video Series-2022: Perimenopause, Signs, Symptoms, and Solutions
  96. Webinars: Previous – 2021 Vision: Practical Steps to Optimize Your Benefit-Risk. Discussions for A New Decade
  97. Webinars: Previous – Breast Cancer
  98. Webinars: Previous – Primary Prevention of Cardiovascular Disease With MHT – Where Are We Now?
  99. Webinars: Previous – The Early Menopausal Patient
  100. What Is Menopausal Hormone Therapy (MHT) and Is It Safe?

Sources

Where may I find the Sources quoted?

You may find the Sources quoted at:

Sources

  1. De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Introduction. Climacteric, 2016;19:4:313 https://www.imsociety.org/wp-content/uploads/2020/08/global-consensus-hrt-2016-06.pdf Accessed: 09 May 2022
  2. De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Introduction. Climacteric, 2016;19:4:313 https://www.imsociety.org/wp-content/uploads/2020/08/global-consensus-hrt-2016-06.pdf Accessed: 09 May 2022
  3. De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Introduction. Climacteric, 2016;19:4:313 https://www.imsociety.org/wp-content/uploads/2020/08/global-consensus-hrt-2016-06.pdf Accessed: 09 May 2022
  4. De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Introduction. Climacteric, 2016;19:4:313 https://www.imsociety.org/wp-content/uploads/2020/08/global-consensus-hrt-2016-06.pdf Accessed: 09 May 2022
  5. De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Section A: Benefit/Risk Profile of MHT. Climacteric, 2016;19:4:313 https://www.imsociety.org/wp-content/uploads/2020/08/global-consensus-hrt-2016-06.pdf Accessed: 09 May 2022
  6. Menopause Glossary: V – Vasomotor Symptoms. North American Menopause Society http://www.menopause.org/for-women/menopause-glossary#V Accessed: 09 May 2022
  7. De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Section B: General Principles Governing the Use of MHT. Climacteric, 2016;19:4:314 https://www.imsociety.org/wp-content/uploads/2020/08/global-consensus-hrt-2016-06.pdf Accessed: 09 May 2022

Topic Last Updated: 09 May 2022 – Topic Last Reviewed: 09 May 2022
Print Friendly, PDF & Email
/by